Healthcare Industry News: Orsiro
News Release - April 10, 2019
BIOTRONIK Launches PK Papyrus Covered Coronary Stent in the USALifesaving Solution Now Available Nationwide for Treatment of Acute Coronary Artery Perforations
LAKE OSWEGO, Ore., April 10, 2019 -- (Healthcare Sales & Marketing Network) -- BIOTRONIK today announced the United States (US) commercial launch of the PK Papyrus« covered coronary stent system for use in the emergency treatment of acute coronary perforations.1,2
More than 800,000 percutaneous coronary intervention procedures are performed annually in the US3 and fewer than 8,000 require a covered stent, classifying PK Papyrus as a Humanitarian Use Device. The ultrathin strut, single-stent design and unique electrospun polyurethane membrane expands treatment options and is designed to reduce the high rate of adverse outcomes associated with coronary artery perforations.
"The availability of PK Papyrus marks a long-overdue advancement in the field of interventional cardiology," said Ryan Walters, President of BIOTRONIK, Inc. "Clinicians can now rely on a low-profile covered stent during critical cardiac emergencies. In situations where every second counts, physicians can trust PK Papyrus to deliver quickly. BIOTRONIK's covered stent is designed to save more lives and to help avoid emergency bypass surgeries, which come with increased risk for patients and can be costly for hospitals. This is innovation that matters for hospital administrators, physicians and their patients, who deserve the best outcomes."
PK Papyrus is the first FDA-approved device for the treatment of acute coronary artery perforations in nearly two decades. It is available in 17 sizes and is the only 5 French compatible4 covered coronary stent on the US market. BIOTRONIK's covered stent is 58 percent more flexible,5 and has a 23 percent smaller crossing profile compared to Graftmaster,6 which has a layered dual-stent design and is the only other covered coronary stent available in the US.
Following the February 2019 approval and availability of Orsiro, the only FDA-approved ultrathin strut drug-eluting stent, the launch of PK Papyrus further strengthens BIOTRONIK's vascular intervention portfolio in the US. PK Papyrus received CE mark in 2013 and was approved for use by the FDA in late 2018. For more information about PK Papyrus or the Institutional Review Board process required to use the covered stent, visit www.PKPapyrus.com or call 800-547-0394.
BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. BIOTRONIK has US offices in New York City and Lake Oswego, Oregon.
For more information, visit: www.biotronik.com
1 Humanitarian Device. Authorized by Federal law for use in the treatment of acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5.0 mm in diameter. The effectiveness of this device for this use has not been demonstrated.
2 Institutional Review Board approval is required for use.
3 Decision Resources Group, Medtech 360, Interventional Cardiology Devices Market Analysis, US 2017.
4 5F compatible for ° 2.5-4.0 mm.
5 Compared to Jostent Graftmaster 3.0/16 (BIOTRONIK data on file).
6 Compared to Graftmaster 2.8/16 (BIOTRONIK data on file).
PK Papyrus is a trademark or registered trademark of the BIOTRONIK Group of Companies.
Jostent and Graftmaster are registered trademarks of the Abbott Group of Companies.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.